Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,699 result(s) found for: Chemistry. Displaying page 77 of 85.
    «« First « Previous 73  74  75  76  77  78  79  80  81  Next» Last»»
    EudraCT Number: 2014-003198-40 Sponsor Protocol Number: DFI13803 Start Date*: 2015-02-19
    Sponsor Name:Genzyme Corporation
    Full Title: A phase 1/2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of olipudase alfa in pediatric patients...
    Medical condition: Patients with acid sphingomyelinase deficiency (Niemann-Pick disease)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10041515 Sphingomyelin lipidosis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003400-39 Sponsor Protocol Number: NGLU-CL02 Start Date*: 2014-07-15
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
    Medical condition: Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo B
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10056918 Sanfilippo's syndrome LLT
    19.0 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2005-003630-18 Sponsor Protocol Number: ICLA-09-CSI2 Start Date*: 2006-01-31
    Sponsor Name:Arpida AG
    Full Title: Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections
    Medical condition: Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic stre...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) DE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001119-30 Sponsor Protocol Number: 2B3-101-CR-001 Start Date*: 2011-06-22
    Sponsor Name:to-BBB technologies B.V.
    Full Title: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.
    Medical condition: Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001769-34 Sponsor Protocol Number: 102-240-02 Start Date*: 2012-10-02
    Sponsor Name:AnaMar AB
    Full Title: A double-blind, placebo controlled, parallel-group, randomised study of safety, tolerability and efficacy of AMAP102 in patients with osteoarthritis.
    Medical condition: Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10019115 Hand osteoarthritis LLT
    16.1 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000599-18 Sponsor Protocol Number: P903-09 Start Date*: 2008-03-25
    Sponsor Name:Cerexa, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone in the Treatment of Adult Subjects with Community-Acquired ...
    Medical condition: Adult Subjects with Community-Acquired Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) HU (Completed) AT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-002860-26 Sponsor Protocol Number: TR701-113 Start Date*: 2011-12-21
    Sponsor Name:Trius Therapeutics, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10-Day Linezolid for the Treatment of...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005256-33 Sponsor Protocol Number: 1182.107 Start Date*: 2007-09-14
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Ensayo clínico multicéntrico, aleatorizado y abierto para evaluar tres dosis de Tipranavir potenciado con dosis bajas de ritonavir (500mg/200mg una vez al día, 250mg/100 mg dos veces al día y 500 m...
    Medical condition: Los pacientes de este estudio deben ser varones y mujeres con edades comprendidas entre los 18 y los 65 años de edad infectados por VIH-1 y no tratados anteriormente con antirretrovirales.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005449-43 Sponsor Protocol Number: MORAb-003-003 PR Start Date*: 2009-10-29
    Sponsor Name:Morphotek, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory ...
    Medical condition: Platinum-Resistant or Refractory Relapsed Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016719-39 Sponsor Protocol Number: 050901 Start Date*: 2010-04-07
    Sponsor Name:Baxter Innovations GmbH
    Full Title: IMMUNINE – Purified Factor IX Concentrate Virus-Inactivated: A Phase IV, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors i...
    Medical condition: To expose up to 50 patients aged 12-64 years, and approximately 20 pediatric patients up to 11 years of age with severe or moderately severe hemophilia B to IMMUNINE for a period of approximately 2...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004451-35 Sponsor Protocol Number: MRTSH01505 Start Date*: 2007-03-13
    Sponsor Name:Genzyme Europe BV
    Full Title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multi...
    Medical condition: Nodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the nor...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043808 Thyrotropin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004967-21 Sponsor Protocol Number: ET743-OVC-1001 Start Date*: 2008-10-20
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
    Medical condition: - to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in subjects with advanced solid tumor malignancies when administered at a ther...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007050 Cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017174-20 Sponsor Protocol Number: EMR701165_023 Start Date*: 2010-03-15
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering...
    Medical condition: Idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016667-11 Sponsor Protocol Number: C10953/3071 Start Date*: 2010-04-29
    Sponsor Name:Cephalon, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...
    Medical condition: Major Depression Associated With Bipolar I Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016634-27 Sponsor Protocol Number: C10953/3072 Start Date*: 2010-06-03
    Sponsor Name:Cephalon, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...
    Medical condition: Major Depression Associated With Bipolar I Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001642-16 Sponsor Protocol Number: TAK-390MR_108 Start Date*: 2015-04-24
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 ...
    Medical condition: Acid-Related Disorders in Infants aged 1 to 11 months
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    17.1 100000004856 10000479 Acid reflux (oesophageal) LLT
    17.1 100000004856 10019326 Heartburn LLT
    17.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001962-13 Sponsor Protocol Number: CBYL719X2105J Start Date*: 2012-11-29
    Sponsor Name:Novartis Farmaceutica S.A
    Full Title: A phase Ib/II open-label, multi-center study of the combination of BYL719 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors
    Medical condition: Solid tumors Hormone receptor positive breast cancer Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000326-54 Sponsor Protocol Number: C16014 Start Date*: 2013-10-08
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Dia...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001485-29 Sponsor Protocol Number: G1T38-02 Start Date*: 2017-03-21
    Sponsor Name:G1 Therapeutics, Inc
    Full Title: Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Bre...
    Medical condition: Hormone Receptor-Positive, HER2 Negative Metastatic Breast Cancer after Endocrine Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000319-18 Sponsor Protocol Number: FW-UC-001 Start Date*: 2018-02-07
    Sponsor Name:FIRST WAVE BIOPHARMA INCORPORATION
    Full Title: A phase I/IIa, open-label, three-stage, study to investigate the safety, the efficacy and the pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Proct...
    Medical condition: Active ulcerative proctitis or ulcerative procto-sigmoiditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10036783 Proctitis ulcerative PT
    20.0 10017947 - Gastrointestinal disorders 10036789 Proctosigmoiditis LLT
    20.1 10017947 - Gastrointestinal disorders 10045362 Ulcerative (chronic) proctosigmoiditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 73  74  75  76  77  78  79  80  81  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 20:03:42 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA